NEO GENOMICS

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



KRAS Mutation Analysis

Alternative Name
KRAS Gene Sequencing, KRAS Exons 2-4 (includes G12C mutation)

Methodology
Molecular

Test Description
Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing is available separately or in combination with BRAF, HRAS and NRAS in the RAS/RAF Panel.

KRAS testing in non-small cell lung cancer may provide prognostic information, predict poor response to EGFR tyrosine kinase inhibitors, and inform on possible response to targeted therapy such as sotorasib. Please see alsoKRAS (G12C) Mutation Analysis for NSCLC, part of a sponsored testing program for stage IV NSCLC patients.

Clinical Significance
Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing in non-small cell lung cancer may provide prognostic information and predict poor response to EGFR tyrosine kinase inhibitors.

Specimen Requirements
- **FFPE solid tumor tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
- **Fine needle aspirate (FNA):** FFPE cell blocks are acceptable. Requisition must note specimen is FNA. Fresh cells and smears are not acceptable.

Storage & Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81275, 81276

Medicare MolDX CPT Code(s)*
81479

New York Approved
Yes

Level of Service
Global

Turnaround Time

7 days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

Rev. 042524